Earli on Bioeconhttps://en.bioecon.ru/companies/earli/Recent content in Earli on BioeconHugoen-USMon, 20 Jul 2026 14:33:00 +0700Synthetic biomarkershttps://en.bioecon.ru/technology/synthetic-biomarkers/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/synthetic-biomarkers/Engineered, exogenous reporter molecules — activity-based nanosensors, synthetic gene circuits and volatile-organic-compound probes — administered to a patient to generate an amplified, easily measured disease signal that no endogenous biomarker naturally produces: Glympse Bio, Earli and ZymoSense in the US, and Owlstone Medical’s EVOC breath-probe platform in the UK.